ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

discussed ADT-sparing approaches in both the metastatic castrate sensitive and resistant settings.

Related Keywords

United States ,New York ,Toronto ,Ontario ,Canada ,Chicago ,Illinois ,Crawford ,Memorial Sloan Kettering Cancer Center ,American ,Karen Autio ,Karena Autio ,European Association Of Urology ,American Society Of Clinical Oncology ,Twitter ,Oncology Group ,National Comprehensive Cancer Network ,University Of Toronto ,Society Of Urologic Oncology ,Genitourinary Oncologist Early Drug Development Specialist ,American Urological Association ,Clinical Oncology ,Annual Meeting ,Prostate Cancer Consensus Conference ,European Association ,Southwest Oncology Group ,Assistant Attending Physician ,Genitourinary Oncologist ,Early Drug Development Specialist ,Rashid Sayyid ,Urologic Oncology ,Clinical Fellow ,Comprehensive Treatment ,Oligometastatic Cancers ,Long Term Results ,Stereotactic Ablative Radiation ,Oligometastatic Prostate Cancerthe ,Metastasis Directed Therapy ,Intermittent Hormone Therapy ,Oligometastatic Prostate Cancer ,Advanced Prostate Cancer Consensus Conference ,